Cargando…

CD248: A therapeutic target in cancer and fibrotic diseases

CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells,...

Descripción completa

Detalles Bibliográficos
Autor principal: Teicher, Beverly A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398180/
https://www.ncbi.nlm.nih.gov/pubmed/30847027
http://dx.doi.org/10.18632/oncotarget.26590
_version_ 1783399536280993792
author Teicher, Beverly A.
author_facet Teicher, Beverly A.
author_sort Teicher, Beverly A.
collection PubMed
description CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells, by the pericyte component of tumor vasculature and by mesenchymal cells in some fibrotic diseases. CD248 is being targeted by several experimental therapeutics including antibodies, antibody drug conjugates, as an antigen for CART cells and in therapeutic vaccines. Although the function of CD248 has yet to be fully elucidated, this protein is a potential broad scope therapeutic target.
format Online
Article
Text
id pubmed-6398180
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-63981802019-03-07 CD248: A therapeutic target in cancer and fibrotic diseases Teicher, Beverly A. Oncotarget Review CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells, by the pericyte component of tumor vasculature and by mesenchymal cells in some fibrotic diseases. CD248 is being targeted by several experimental therapeutics including antibodies, antibody drug conjugates, as an antigen for CART cells and in therapeutic vaccines. Although the function of CD248 has yet to be fully elucidated, this protein is a potential broad scope therapeutic target. Impact Journals LLC 2019-01-29 /pmc/articles/PMC6398180/ /pubmed/30847027 http://dx.doi.org/10.18632/oncotarget.26590 Text en Copyright: © 2019 Teicher et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Teicher, Beverly A.
CD248: A therapeutic target in cancer and fibrotic diseases
title CD248: A therapeutic target in cancer and fibrotic diseases
title_full CD248: A therapeutic target in cancer and fibrotic diseases
title_fullStr CD248: A therapeutic target in cancer and fibrotic diseases
title_full_unstemmed CD248: A therapeutic target in cancer and fibrotic diseases
title_short CD248: A therapeutic target in cancer and fibrotic diseases
title_sort cd248: a therapeutic target in cancer and fibrotic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398180/
https://www.ncbi.nlm.nih.gov/pubmed/30847027
http://dx.doi.org/10.18632/oncotarget.26590
work_keys_str_mv AT teicherbeverlya cd248atherapeutictargetincancerandfibroticdiseases